A systematic review of radiotherapy for primary renal cell carcinoma


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Renal cell cancer accounts for 2% of all cancers. The gold standard for managing patients with no evidence of distant metastasis renal cell cancer remains is complete surgical resection. The clinical data investigating preoperative radiotherapy failed to reveal benefited from this methods. The role of routine postoperative radiotherapy in the management of renal cell cancer is not established in patients with localized disease after complete surgical resection. Renal cell cancer is radioresistant tumor for conventional radiation therapy. Although renal cell carcinoma is related to radioresistant tumors, in recent years new promising directions in radiation therapy have become apparent. To overcome the radioresistance of renal cell carcinoma, the use of modified radiation therapy regimens with high doses per fraction is justified. A new technologies of radiation therapy, which include stereotactic radiation therapy allows to accurately deliver doses of ionizing radiation to a tumor, without the risk of damage to neighboring tissues and organs. Recent data showing that with the use of high-precision methods, such as SBRT, unresectable local renal cell carcinoma can successfully be treated with durable local control and low toxicity. Nonetheless, prospective, randomized trials and comparative effectiveness studies are needed to further evaluate this ablative modality in the treatment of renal cell carcinoma.

全文:

受限制的访问

作者简介

I. Gladilina

N.N. Blokhin National Medical Research Center of Oncology; Pirogov Russian National Research Medical University

Email: 0152@mail.ru
leading Researcher of the Radiotherapy Department ICEER; professor, Oncology and radiotherapy of the medical faculty; Doctor of Medical Science, Docent Moscow, Russia; Moscow, Russia

M. Shabanov

Pirogov Russian National Research Medical University

Email: 0152@mail.ru
leading Researcher, Department of the Pathology; Doctor of Medical Science, Professor Moscow, Russia

N. Kushlinskii

N.N. Blokhin National Medical Research Center of Oncology

head of the laboratory of clinical biochemistry ICEER; MD, Professor, Academician of the Russian Academy of Sciences Moscow, Russia

P. Bliganov

N.N. Blokhin National Medical Research Center of Oncology

Email: pavelbliganov@yandex.ru
resident doctor; oncology FAPE Moscow, Russia

A. Sergeev

Tver State Medical University

head of the Department of General Surgery; Doctor of Medical Science, assistant professor Tver, Russia

参考

  1. Матвеев В.Б., Маркова А.С. Рак почки: что нового в 2018 году. Онкоурология. 2018;14(4):48-52). doi: 10.17650/1726-9776-2018-14-4-48-52.
  2. De Felice F., Tombolini V. Radiation therapy in renal cell carcinoma. Crit Rev Oncol Hematol. 2018;128:82-87. doi: 10.1016/j.critrevonc.2018.06.002.
  3. Ferlay J., Bray F., Pisani P., Parkin D.M. GLOBOCAN 2000: Cancer incidence, Mortality and prevalence Worldwide. IARC Press. Lion. 2001.
  4. Davydov M.I., Matveev V.B., Volkova M.I., et al. Surgical treatment of renal cell carcinoma with advanced tumor invasion of the inferior vena cava: Cancer Urology. 2017;13(1):27-36. doi: 10.17650/1726-9776-2017-13-1-27-36.
  5. Blanco A.I., Teh B.S., Amato R.J. Role of Radiation Therapy in the Management of Renal Cell Cancer. Cancers. 2011 ;3(4):4010-4023. doi: 10.3390/cancers3044010.
  6. Tselis N., Chatzikonstantinou G. Treating the Chameleon: Radiotherapy in the management of Renal Cell Cancer. Clin Transl Radiat Oncol. 2019;16:7-14. doi: 10.1016/j.ctro.2019.01.007.
  7. Гладилина И.А., Клеппер Л.Я., Ефимкина Ю.В., и соавт. Гипофракционированный ускоренный режим лучевой терапии у больных после органосохраняющих операций по поводу III стадий рака молочной железы. Опухоли женской репродуктивной системы. 2016;12(3):17-23). doi: 10.17650/1994-4098-2016-12-3-17-22.
  8. Rühle A., Andratschke N, Siva S., Guckenberger M. Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma? Clinical and Translational Radiation Oncology. 2019;18:104-112. doi: 10.1016/j.ctro.2019.04.012.
  9. Parashar B., Charan Patro K., Smith M., et al. Role of Radiation Therapy for Renal Tumors. Semin Intervent Radiol. 2014;31(1):86-90. doi: 10.1055/s-0033-1363847.
  10. Tunio M.A., Hashmi A., Rafi M. Need for a new trial to evaluate postoperative radiotherapy in renal cell carcinoma: a meta-analysis of randomized controlled trials. Ann Oncol. 2010;21:1839-1845. doi: 10.1093/annonc/mdq028.
  11. Каприн А.Д., Исайчев А.К. Использование дополнительных методов в лечении местнораспространенного рака почки Т3аШМ0. Вестник РНЦРР МЗ РФ. 2006;6. http://vestnik.mcrr.ru/vestnik/v6/papers/isav6.htm.
  12. Bhatt R.S., Landis D.M., Zimmer M., et al. Hypoxia-inducible factor-2a: Effect on radiationsensitivity and differential regulation by an mTOR inhibitor. BJU Int. 2008; 102(3):358-363. doi: 10.1111/j.1464-410X.2008.07558.x.
  13. Hui Z., Tretiakova M., Zhang Z., et al. Radiosensitization by inhibiting STAT1 in renal cell carcinoma.Int J RadiatOncol Biol Phys. 2009;73(1):288-95. doi: 10.1016/j.ijrobp.2008.08.043.
  14. Siva S., Chesson B., Bressel M., et al. TROG 15.03 phase II clinical trial of Focal Ablative Stereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II. BMC Cancer. 2018;18(1):1030. doi: 10.1186/s12885-018-4916-2.
  15. Walsh L., Stanfield J.L., Cho L.C., Chang C.H. Efficacy of ablative high-dose per-fraction radiation for implanted human renal cell cancer in a nude mouse model. Eur Urol. 2006;50(4):795-800. doi: 10.1016/j.eururo.2006.03.021.
  16. Swaminath A., Chu W. Stereotactic body radiotherapy for the treatment of medically inoperable primary renal cell carcinoma: Current evidence and future directions. Can Urol Assoc J. 2015;9(7-8):275-280. doi: 10.5489/cuaj.2900.
  17. Siva S., Kothari G., Muacevic A., Louie A.V. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach. Nat Rev Urol. 2017;14(9):549-563. doi: 10.1038/nrurol.2017.87.
  18. Siva S., Pham D., Gill S., et al. A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma. BJU Int. 2012;110(11 Pt B):E737-743. doi: 10.1111/j.1464-410X.2012.11550.x.
  19. Wersäll P.J., Blomgren H., Lax I., et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol. 2005;77(1):88-95. doi: 10.1016/j.radonc.2005.03.022.
  20. Francolini G., Detti B., Ingrosso G., et al. Stereotactic body radiation therapy (SBRT) on renal cell carcinoma, an overview of technical aspects, biological rationale and current literature. Crit Rev Oncol Hematol. 2018;131:24-29. doi: 10.1016/j.critrevonc.2018.08.010.
  21. Siva S., Louie A.V., Warner A., et al. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Cancer. 2018;124(5):934-942. doi: 10.1002/cncr.31156.
  22. Beitler J.J., Makara D., Silverman P., Lederman G. Definitive, high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma. Am J Clin Oncol. 2004;27(6):646-648. doi: 10.1097/01.coc.0000145289.57705.07.
  23. Rachela C., James Yu. Radiation Therapy for Renal Cell Carcinoma. Kidney Cancer. 2019;3(1):1-6. doi: 10.3233/KCA-180040.
  24. Rohann J.M., Alexander V.L. Stereotactic Radiotherapy as a Treatment Option for Renal Tumors in the Solitary Kidney: A Multicenter Analysis from the IROCK. Multicenter Study J Urol. 2019;201(6):1097-1104. doi: 10.1097/JU.0000000000000111.
  25. Siva S., Rohann J.M. Stereotactic Ablative Radiotherapy for >T1b Primary Renal Cell Carcinoma: A Report From the International Radiosurgery Oncology Consortium for Kidney (IROCK), Int J Radiat Oncol Biol Phys. 2020;108(4):941-949. doi: 10.1016/j.ijrobp.2020.06.014.
  26. Yamamoto T., Yoshihide K. Stereotactic body radiotherapy for kidney cancer: a 10-year experience from a single institute. Journal of Radiation Research. 2021;62(3):533-539. doi: 10.1093/jrr/rrab031.
  27. Siva S., Pham D., Kron T., et al. Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: A prospective clinical trial. BJU Int. 2017;120(5):623-630.
  28. Siva S., Ellis R.J., Ponsky L., et al. Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma. Future Oncol. 2016;12(5):637-645.
  29. Sonier M., Chu W., Lalani N., et al. Evaluation of kidney motion and target localization in abdominal SBRT patients. J. Appl. Clin. Med. Phys. 2017;(6):429-433. doi: 10.1120/jacmp.v17i6.6406.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2022
##common.cookie##